Literature DB >> 18077630

Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-beta-lactamase-producing Escherichia coli.

Wolfgang A Krueger1, Volkhard A J Kempf, Manou Peiffer, Udo Nagele, Klaus E Unertl, Torsten H Schroeder.   

Abstract

A 25-year-old female was admitted to our intensive care unit with septic shock and multiorgan failure caused by extended-spectrum beta-lactamase-producing Escherichia coli originating from the right renal pelvis. A 16-day course of treatment with meropenem reversed the septic condition, but the infection recurred thereafter. The patient recovered fully after therapy was changed to tigecycline.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18077630      PMCID： PMC2238119          DOI： 10.1128/JCM.01340-07

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  7 in total

1.  Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofiltration.

Authors:  Wolfgang A Krueger; Gertraud Neeser; Harald Schuster; Torsten H Schroeder; Edgar Hoffmann; Alexandra Heininger; Hans-Juergen Dieterich; Helmuth Forst; Klaus E Unertl
Journal:  Chemotherapy       Date:  2003-12       Impact factor: 2.544

Review 2.  The pharmacokinetic and pharmacodynamic profile of tigecycline.

Authors:  Alison K Meagher; Paul G Ambrose; Thaddeus H Grasela; Evelyn J Ellis-Grosse
Journal:  Clin Infect Dis       Date:  2005-09-01       Impact factor: 9.079

3.  Correlation between candiduria and departmental antibiotic use.

Authors:  M Weinberger; S Sweet; L Leibovici; S D Pitlik; Z Samra
Journal:  J Hosp Infect       Date:  2003-03       Impact factor: 3.926

4.  Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration.

Authors:  W A Krueger; T H Schroeder; M Hutchison; E Hoffmann; H J Dieterich; A Heininger; C Erley; A Wehrle; K Unertl
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

5.  Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.

Authors:  Wolfgang A Krueger; Jurgen Bulitta; Martina Kinzig-Schippers; Cornelia Landersdorfer; Ulrike Holzgrabe; Kurt G Naber; George L Drusano; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

6.  Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.

Authors:  R Phillip Dellinger; Jean M Carlet; Henry Masur; Herwig Gerlach; Thierry Calandra; Jonathan Cohen; Juan Gea-Banacloche; Didier Keh; John C Marshall; Margaret M Parker; Graham Ramsay; Janice L Zimmerman; Jean-Louis Vincent; M M Levy
Journal:  Intensive Care Med       Date:  2004-03-03       Impact factor: 17.440

Review 7.  Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role.

Authors:  Jason A Roberts; Jennifer Paratz; Elizabeth Paratz; Wolfgang A Krueger; Jeffrey Lipman
Journal:  Int J Antimicrob Agents       Date:  2007-04-17       Impact factor: 5.283
  7 in total
  8 in total

1.  Ertapenem-induced reduction in valproate levels: case report and review of the literature.

Authors:  Duane Bates; Michael Parkins; Keltie Duggan
Journal:  Can J Hosp Pharm       Date:  2010-07

2.  Tigecycline treatment of urinary tract infection and prostatitis: case report and literature review.

Authors:  Duane Bates; Mike Parkins; Robin Hellweg; Kimberly Gibson; Jennifer M Bugar
Journal:  Can J Hosp Pharm       Date:  2012-05

Review 3.  Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease.

Authors:  Yun Cai; Rui Wang; Beibei Liang; Nan Bai; Youning Liu
Journal:  Antimicrob Agents Chemother       Date:  2010-12-20       Impact factor: 5.191

4.  Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis.

Authors:  Burke A Cunha
Journal:  J Clin Microbiol       Date:  2009-05       Impact factor: 5.948

5.  Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective.

Authors:  Daniel Curcio
Journal:  J Clin Microbiol       Date:  2008-05       Impact factor: 5.948

6.  Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine.

Authors:  Michael J Satlin; Christine J Kubin; Jill S Blumenthal; Andrew B Cohen; E Yoko Furuya; Stephen J Wilson; Stephen G Jenkins; David P Calfee
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

7.  Current and novel antibiotics against resistant Gram-positive bacteria.

Authors:  Federico Perez; Robert A Salata; Robert A Bonomo
Journal:  Infect Drug Resist       Date:  2008-09-09       Impact factor: 4.003

8.  Efficacy and safety of tigecycline for complicated urinary tract infection: a systematic review.

Authors:  Yang-Xi Liu; Ke-Jia Le; Hong-Yao Shi; Zai-Li Zhang; Min Cui; Han Zhong; Yue-Tian Yu; Zhi-Chun Gu
Journal:  Transl Androl Urol       Date:  2021-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.